(Sharecast News) - Biotechnology firm Oxford Biomedica said on Tuesday that strong commercial momentum and expanding manufacturing capacity continued to underpin its long‑term growth outlook, as the group reiterated full‑year guidance alongside a solid first‑half performance.
Oxford Biomedica delivered 10% constant‑currency revenue growth in H126 to £80.2m, supported by demand across...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE